Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Brunetti

Showing results (101-110 of 141) with videos related to

Pageof 15
Sort By:
Biochemistry|August 26, 1998
Design of selective eglin inhibitors of HCV NS3 proteinaseF Martin, N Dimasi, C Volpari, et al.
Journal of Virology|October 6, 1997
Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoiresN Dimasi, F Martin, C Volpari, et al.
Protein Engineering|May 1, 1997
Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 proteaseF Martin, C Volpari, C Steinkuhler, et al.
Biomedical Reports|March 20, 2020
Clinical and economic effect of administration of red blood product transfusions in an outpatient supportive care cancer serviceAndrea Sbrana, Federico Paolieri, Francesco Bloise, et al.
Oncology|October 2, 2004
Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancerC Barone, A Cassano, C Pozzo, et al.
Diabetes, Nutrition & Metabolism|July 13, 2004
Characteristics of Type 2 diabetic patients cared for by general practitioners either with medical nutrition therapy alone or with hypoglycaemic drugsA V Ciardullo, M Brunetti, M M Daghio, et al.
The Journal of Biological Chemistry|May 16, 2000
Probing the active site of the hepatitis C virus serine protease by fluorescence resonance energy transferD Fattori, A Urbani, M Brunetti, et al.
Biochemistry|February 26, 2000
Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 proteaseF Narjes, M Brunetti, S Colarusso, et al.
Natural Immunity|March 1, 1994
Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genesP Musiani, A Modesti, M Brunetti, et al.
Cell|August 16, 2014
State-dependent architecture of thalamic reticular subnetworksMichael M Halassa, Zhe Chen, Ralf D Wimmer, et al.
Pageof 15

Showing results (101-110 of 141) with videos related to

Sort By:
Pageof 15
Biochemistry|August 26, 1998
Design of selective eglin inhibitors of HCV NS3 proteinaseF Martin, N Dimasi, C Volpari, et al.
Journal of Virology|October 6, 1997
Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoiresN Dimasi, F Martin, C Volpari, et al.
Protein Engineering|May 1, 1997
Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 proteaseF Martin, C Volpari, C Steinkuhler, et al.
Biomedical Reports|March 20, 2020
Clinical and economic effect of administration of red blood product transfusions in an outpatient supportive care cancer serviceAndrea Sbrana, Federico Paolieri, Francesco Bloise, et al.
Oncology|October 2, 2004
Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancerC Barone, A Cassano, C Pozzo, et al.
Diabetes, Nutrition & Metabolism|July 13, 2004
Characteristics of Type 2 diabetic patients cared for by general practitioners either with medical nutrition therapy alone or with hypoglycaemic drugsA V Ciardullo, M Brunetti, M M Daghio, et al.
The Journal of Biological Chemistry|May 16, 2000
Probing the active site of the hepatitis C virus serine protease by fluorescence resonance energy transferD Fattori, A Urbani, M Brunetti, et al.
Biochemistry|February 26, 2000
Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 proteaseF Narjes, M Brunetti, S Colarusso, et al.
Natural Immunity|March 1, 1994
Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genesP Musiani, A Modesti, M Brunetti, et al.
Cell|August 16, 2014
State-dependent architecture of thalamic reticular subnetworksMichael M Halassa, Zhe Chen, Ralf D Wimmer, et al.
Pageof 15